New antibody shows promise in shrinking HER2+ colorectal tumors before surgery

NCT ID NCT07405476

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether giving zanidatamab before surgery can shrink tumors in people with HER2+ colorectal cancer. About 38 participants will receive the drug intravenously, then undergo surgery. The study measures how much the tumor regresses and whether cancer returns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zanidatamab (a monoclonal antibody given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for HER2+ colorectal cancer, potentially shrinking tumors before surgery and reducing recurrence risk.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. Zanidatamab may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer colorectal carcinoma colorectal neoplasm malignant colon neoplasm rectal cancer rectal carcinoma rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CARCINOMA COLORECTAL CARCINOMA RECTAL CARCINOMA STAGE I COLON CANCER AJCC V8 STAGE I COLORECTAL CANCER AJCC V8 STAGE I RECTAL CANCER AJCC V8 STAGE II COLON CANCER AJCC V8 STAGE II COLORECTAL CANCER AJCC V8 STAGE II RECTAL CANCER AJCC V8 STAGE III COLON CANCER AJCC V8 STAGE III COLORECTAL CANCER AJCC V8 STAGE III RECTAL CANCER AJCC V8

Contacts and locations

Locations

Emory Decatur Hospital
RECRUITING

Decatur, Georgia, 30033, United States
Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.